These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 18986533

  • 1. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK, Chadha MK, Litwin A, Trump DL.
    J Hematol Oncol; 2008 Nov 05; 1():21. PubMed ID: 18986533
    [Abstract] [Full Text] [Related]

  • 2. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
    El-Gabry EA, Strup SE, Gomella LG.
    Tech Urol; 2000 Sep 05; 6(3):221-2. PubMed ID: 10963494
    [Abstract] [Full Text] [Related]

  • 3. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M, Lacombe L, Fradet Y.
    Urology; 2010 Nov 05; 76(5):1189-93. PubMed ID: 20303155
    [Abstract] [Full Text] [Related]

  • 4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 05; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar 05; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 6. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJ.
    J Urol; 1997 May 05; 157(5):1731-5. PubMed ID: 9112515
    [Abstract] [Full Text] [Related]

  • 7. [Solitary peritoneal carcinomatosis in prostate cancer].
    Brehmer B, Makris A, Wellmann A, Jakse G.
    Aktuelle Urol; 2007 Sep 05; 38(5):408-9. PubMed ID: 17907070
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar 05; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 10. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.
    BJU Int; 2006 Jun 05; 97(6):1184-9. PubMed ID: 16686709
    [Abstract] [Full Text] [Related]

  • 11. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
    Rapkiewicz A, Gorokhovsky R, Farcon E, Das K.
    Diagn Cytopathol; 2008 Jul 05; 36(7):499-502. PubMed ID: 18528888
    [Abstract] [Full Text] [Related]

  • 12. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
    Okegawa T, Nutahara K, Higashihara E.
    Int J Urol; 2010 Nov 05; 17(11):950-5. PubMed ID: 20807265
    [Abstract] [Full Text] [Related]

  • 13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 05; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 14. [Bicalutamide].
    Taéron C.
    Rev Infirm; 2010 Mar 05; (158):47-9. PubMed ID: 20383962
    [No Abstract] [Full Text] [Related]

  • 15. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.
    Prostate; 2012 Jun 01; 72(8):875-85. PubMed ID: 22072572
    [Abstract] [Full Text] [Related]

  • 16. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.
    Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, Marzi S, Landoni V, Fowler J, Strigari L.
    Int J Radiat Oncol Biol Phys; 2010 Sep 01; 78(1):11-8. PubMed ID: 20047800
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB, Ryan CW, Stadler WM, Vogelzang NJ.
    BJU Int; 2005 Oct 01; 96(6):787-90. PubMed ID: 16153201
    [Abstract] [Full Text] [Related]

  • 18. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
    Barbón JJ, González-Tuero J, Gay LL, Pérez-García FJ, Sampedro A.
    Arch Soc Esp Oftalmol; 2007 Nov 01; 82(11):715-7. PubMed ID: 17979041
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
    Molenaar JP, Baten A, Blokx WA, Hoogendam A.
    Eur Urol; 2009 Nov 01; 56(5):874-7; quiz 876. PubMed ID: 19171417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.